Sugi Predict

Sugi Predict / Compounds / SCHEMBL614168

SCHEMBL614168

SCHEMBL614168

CC1(C)OB(c2ccnc(N)c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 4/20 0.42
▸ NOS2 P35228 4/20 0.42
▸ NOS1 P29475 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ LPL P06858 12/20 0.41
▸ LIPG Q9Y5X9 12/20 0.41
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ F11 P03951 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419367 1.00 NOS3 (0.42) NOS3NOS2NOS1KDM4EMEN1
SCHEMBL27364270 0.84 LPL (0.37) NOS3NOS2NOS1KDM4EMEN1
SCHEMBL253320 0.80 UHRF1 (0.42) LPLLIPGCA1CA2CA9
SCHEMBL29502732 0.80 UHRF1 (0.42) LPLLIPGCA1CA2CA9
SCHEMBL23496480 0.79 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL17053327 0.79 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL12069605 0.79 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL394155 0.79 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL29502754 0.79 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL613614 0.79 LPL (0.47) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4736856-A2 BICYCLIC AMINES AS CDK2 INHIBITORS Incyte Corporation (US) 2026-05-06 — — EP disclosed
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
EP-4041731-B1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORP (US) 2026-02-18 — — EP disclosed
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2026-01-22 — — US disclosed
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-01-20 — — US disclosed
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 — — US disclosed
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 — — US disclosed
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 — — US disclosed
US-12466828-B2 Bicyclic amines as CDK2 inhibitors INCYTE CORPORATION (US) 2025-11-11 — — US disclosed
US-20250340521-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2025-11-06 — — US disclosed
US-7772246-B2 Pyrazole compounds as RAF inhibitors PFIZER INC. (US) 2010-08-10 — — US disclosed
US-7772246-B2 Pyrazole compounds as RAF inhibitors PFIZER INC. (US) 2010-08-10 — — US disclosed
US-7772246-B2 Pyrazole compounds as RAF inhibitors PFIZER INC. (US) 2010-08-10 — — US disclosed
EP-2183243-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS Pfizer Inc. (US) 2010-05-12 — — EP disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
WO-2009016460-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS PFIZER INC. (US) 2009-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221608-A1 PYRAZOLE COMPOUNDS BRAF, RAF1, NRAS NOS3 3044/4885NOS2 3616/4885NOS1 3870/4885
US-12528810-B2 Small molecule inhibitors of DYRK/CLK and uses thereof CLK3, CLK2, CLK1 NOS3 612/4885NOS2 1095/4885NOS1 1593/4885
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 NOS3 3933/4885NOS2 4274/4885NOS1 4490/4885
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CCNA1, CDK1, CCNE1 NOS3 3113/4885NOS2 3629/4885NOS1 1701/4885
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS CCNA1, CCNO, CDK1 NOS3 3605/4885NOS2 4045/4885NOS1 2400/4885
US-20250340521-A1 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME ABL1, ABL2, MUSK NOS3 3321/4885NOS2 3100/4885NOS1 3139/4885
US-12466828-B2 Bicyclic amines as CDK2 inhibitors CDK2, CDK1, CCNI NOS3 3427/4885NOS2 2451/4885NOS1 3446/4885
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 NOS3 3933/4885NOS2 4274/4885NOS1 4490/4885
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3C2B, PIK3C2A, PIK3R1 NOS3 1682/4885NOS2 2073/4885NOS1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.